Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells. It is not known whether receiving standard combination chemotherapy alone is more effective than receiving multiple combination chemotherapy plus peripheral stem cell transplantation for aggressive non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing giving different combination chemotherapy regimens together with peripheral stem cell transplantation to see how well they work in treating patients with newly diagnosed aggressive non-Hodgkin's lymphoma.

Conditions

• Lymphoma

Interventions

BIOLOGICAL

filgrastim

DRUG

CHOP regimen

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

leucovorin calcium

DRUG

melphalan

DRUG

methotrexate

DRUG

methylprednisolone

DRUG

mitoxantrone hydrochloride

DRUG

prednisone

DRUG

therapeutic hydrocortisone

DRUG

vincristine sulfate

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Sponsors & Collaborators

• Swiss Cancer Institute

  lead OTHER

Principal Investigators

• Daniel C. Betticher, MD · Insel Gruppe AG, University Hospital Bern

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1997-04-30

Primary Completion

2004-03-31

Completion

2004-03-31

Countries

• Austria
• Germany
• Greece
• Italy
• Switzerland

Study Locations